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Objectives: The objective of this study was to develop a method to allocate treatment
effects when patients switch medication frequently in longitudinal observational studies
and apply the approach to assess the cost-effectiveness of treatments in the
Schizophrenia Outpatient Health Outcomes (SOHO) study.
Methods: Data were collected on patients at entry to the SOHO study at 3, 6, and
12 months. The 12-month follow-up period was considered as three epochs: 0–3 months,
3–6 months, and 6–12 months. Patients who switched treatment at 3 months had their
new treatment considered as a new baseline observation, as these two 3-month
observations provide two sets of information on the cost-effectiveness of a drug in the first
3 months after initiation. Multivariate regression analysis was used to adjust for baseline
covariates. The model allowed for flexible functional forms, and the cost data were
The Schizophrenia Outpatient Health Outcomes (SOHO) study is funded by Eli Lilly and Company, Windlesham, Surrey, UK. The SOHO study group:
(France) J.-P. Lepine, Hoˆspital Fernand Widal, Paris; I. Gasquet, Hoˆpital Cochin, Paris; (Germany) D. Naber, Universitatskrankenhaus-Eppendorf, Hamburg;
(the Netherlands) C.J. Slooff, Kenniscentrum Schizofrenie, Assen; (Spain) J. Alonso, University of Barcelona, Barcelona; J.M. Haro, Sant Joan de Deu-SMM,
St. Boi, Barcelona; (UK) T. Croudace and P.B. Jones, Addenbrooke’s Hospital, Cambridge; M. Knapp, PSSRU, London School of Economics, London.
We thank at Eli Lilly and Company, Mark Belger for his statistical advice, Jo Cooper for her administrative support, and Diego Novick, Spyridon Tzivelekis,
and Mark Ratcliffe for their comments.
Declaration of interest
Frank Windmeijer received monetary compensation from Eli Lily and Company for econometric advice. Martin Knapp and Josep Maria Haro were paid by
Eli Lily and Company for their participation in the SOHO Advisory Board. Stathis Kontodimas and Jackie Brown are Eli Lilly and Company employees.
460
Epoch analysis for assessing cost-effectiveness
modeled using an exponential mean function. Bootstrapping assessed the uncertainty of
the estimated parameters and incremental cost-effectiveness analysis decision rule.
Results and Conclusions: We show the feasibility of the epoch analysis approach using
data from the SOHO study comparing two antipsychotics. Estimates for the incremental
cost and effectiveness per epoch over the full 12-month period are presented. Using the
estimates of 200 bootstrap samples, we demonstrate how one drug is cost-effective
compared with another.
Keywords: Observational studies, Cost-effectiveness, Longitudinal data, Epoch analysis
Randomized controlled trials (RCTs) are the gold standard
for assessing efficacy and safety of healthcare technologies,
including pharmaceutical products. They can demonstrate
whether a healthcare intervention works in a defined popula-
tion and have a high internal validity, as patients are randomly
allocated to protocol-driven treatments with strict study en-
try criteria. However, these same features may restrict the
generalizability of the findings to the everyday clinical set-
ting. Government agencies, such as the French Transparency
Committee, therefore, request that pharmaceutical compa-
nies demonstrate the effectiveness of their products in an
everyday clinical setting. Observational studies are, thus, a
useful nonexperimental complement to RCTs (9).
Epidemiological observational studies that longitudi-
nally follow-up cohorts of individuals in a naturalistic setting
without randomization to treatment, have traditionally been
performed to determine whether there is an association be-
tween disease status (e.g., heart disease) and exposure to
certain factors (e.g., cholesterol level or smoking) (17). This
type of study design, however, can also be used to determine
whether there is an association between the drugs adminis-
tered and their effectiveness.
Data showing the cost-effectiveness of pharmaceutical
products are also increasingly required for access and re-
imbursement, particularly in the United Kingdom, Canada,
Australia, Sweden, and the Netherlands. Observational stud-
ies are a useful vehicle for determining whether there is a
difference in the costs (and hence cost-effectiveness) associ-
ated with the drugs administered outside of the experimental
setting.
Nonrandomized studies are more prone to bias, however.
They are at particular risk of selection bias if investigators
select patients for treatments on the basis of the characteris-
tics of the patient or their disease, thus leading to systematic
differences between comparison groups (4).
The convention is to adjust for differences in risk or
prognostic factors to avoid confounding. This strategy as-
sumes that the researchers know the most important prog-
nostic factors and that these factors have been measured ap-
propriately in the study (3). Even if appropriate adjustments
can be made, observational studies still pose methodological
problems, as in everyday clinical practice patients may be
prescribed more than one medication and frequently switch
medications. This finding raises the issue of how to attribute
the medication effects to the outcomes of interest. This study
describes a novel method of analysis, the so-called epoch
analysis, to address this issue. It uses the economic analy-
sis conducted as part of the Schizophrenia Outpatient Health
Outcomes (SOHO) study as an illustrative case (6;7), where
the specific outcomes of interest are the incremental cost and
quality-adjusted life-years (QALYs) gained as derived from
the health-related quality of life instrument EQ-5D (Euro-
Qol) (2).
The proposed method of analysis allows alternative esti-
mation approaches to be used to take into account the skewed
nature of the cost data (10). It uses an adaptation of the Man-
ning and Mullahy (10) method for choosing among the alter-
native estimators and uses the Poisson estimator to estimate
the cost models.
SOHO and Schizophrenia
The European SOHO study is the largest naturalistic study
of antipsychotic drugs conducted to date (6;7). It is a 3-year,
prospective, observational study of the outcomes of antipsy-
chotic treatment for schizophrenia in the outpatient setting.
One of the main objectives of SOHO is to understand the
comparative costs and outcomes of therapy for schizophre-
nia with olanzapine versus other antipsychotic medications
in a clinical setting.
The SOHO study is being conducted in ten European
countries with 1,096 investigators participating. A total of
10,972 patients with schizophrenia starting or changing med-
ication in the outpatient setting have been enrolled in SOHO,
undergoing evaluation at regular time intervals (at enrollment
and at 3, 6, 12, 18, 24, 30, and 36 months). Data collected in-
clude patients’ prognostic characteristics and other potential
confounding characteristics; health service resource use such
as medication use, the number of hospital inpatient and out-
patient visits; and patient self-reported EQ-5D health state
classifications (2). Details of the study methods have been
published elsewhere (6;7).
All patient care was at the discretion of the participating
psychiatrist; no specific instructions were included in the
study description. SOHO is essentially observing a window
of 3 years of care in the patient’s schizophrenia treatment
path.
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This study focuses on the economic analysis for the first
12 months. As expected (3), outside of the experimental set-
ting of an RCT, a sizeable proportion of patients (31 percent)
switched their antipsychotic medication during follow-up
or added another antipsychotic medication to their baseline
treatment.
METHODS
Allocation of Treatment Effects
The objective of the analysis is to estimate the treatment ef-
fects on costs and change in EQ-5D tariff or utility score (2)
of the drugs taken by the patients. Difficulties arise with con-
ventional methods of allocating and interpreting such effects
when patients frequently switch medication. With intention-
to-treat analysis, the recommended method for analyzing
RCTs, the treatment effects are attributed to the medication
given at study entry. When patients frequently change med-
ication, this type of analysis could favor less effective med-
ications at study entry if patients are subsequently switched
to more effective medications.
The treatment effects of each drug could be allocated in
proportion to the duration of treatment on the drug, as in an
exposure approach. For example, if drug A was taken for 3
months and drug B subsequently for 9 months, then over the
12-month period, 25 percent of the 12-month effectiveness
would be attributed to drug A and 75 percent to drug B. This
strategy assumes effectiveness is additive and linear with du-
ration, which may not be realistic. The linearity assumption
of course can easily be relaxed, but it is not clear what the
appropriated functional form would be.
A new method of analysis, thus, was needed to attribute
treatment effects directly to the antipsychotic medication
taken by the patients. For the purposes of this data anal-
ysis, we divided the data into three epochs: 0–3 months,
3–6 months, and 6–12 months (hence the name epoch anal-
ysis). To maximize the data used, a patient may contribute
more than one observation per epoch. Each epoch provides
information on the treatment effects during the respective
time period.
Using a hypothetical example, we describe here how
the treatment effects are assigned using the epoch analysis.
During the 12 months of data collection, we have four ob-
servations per patient (enrollment, 3, 6, and 12 months after
enrollment, referred to below as t = 1, 2, 3, and 4).
For simplicity, assume that a patient can receive one of
two drugs during the observation period: drug A or drug B.
Imagine that a patient receives drug A for the whole 12-month
observation period (see Figure 1a). The first epoch provides
information on the treatment effect of drug A over the first
3 months of treatment. The second epoch provides informa-
tion on the treatment effect of drug A over the subsequent
3-month period of treatment conditional on being treated
with drug A during the first 3 months of treatment. The
third epoch provides information on the treatment effect of
drug A over the last six months conditional on having been
treated with drug A during the previous 6 months. Being on
the same treatment in the prior period is instrumental as it
provides the necessary conditions for combining the three
treatment effects to provide a cumulative treatment effect
over the 12-month period.
Now imagine that a second patient switches to drug B
after 3 months of treatment with drug A (see Figure 1b).
The first 3 months of treatment with drug A contributes to
the first epoch, depicted as Epoch 1A. The patient, however,
initiates a new medication at time t = 2, which is effectively
a new baseline observation; hence, the first 3 months of drug
B contribute to the first epoch, depicted as Epoch 1B. For
this patient, two observations contribute to the first epoch:
one for drug A and one for drug B. In this case, data from
the second 6-month observation period cannot be analyzed
as Epoch 2 for drug B as the time period is not consistent
with the analysis (3 months).
A third patient switches medication from drug A to drug
B at observation t = 3 (see Figure 1c). For this patient,
Epoch 1 and Epoch 2 are used as for patient one. Data from
the second 6-month observation period cannot be analyzed
as Epoch 1B, however, as the time period is not consistent
with the analysis (3 months).
As pointed out above, some observation periods for var-
ious patient types are not being used for the estimation of the
treatment effects due to the unequal time periods. As further
observation periods become available with the SOHO data,
a more efficient use of the patient observations may be to
analyze the data in 6-month epochs. However, as most of the
benefits of antipsychotic medications tend to occur during
the first 4 to 6 weeks of treatment, we decided to keep the
duration of the first two epochs as 3 months for the 12-month
data analysis.
Estimation Issues
Multivariate regression analysis was used to examine the
impact of treatment on costs and EQ-5D tariff, adjusting
for confounding effects to take account of selection bias
(4). To allow for flexible treatment effects over time, we
estimate separate coefficients for the different epochs. The
three regression models used to model costs and outcomes
are:
First Epoch. Denote Yit,3 as the dependent variable, cost
or change in EQ-5D tariff, during the first 3-month epoch
for patient i at time t, t ∈ {2, 3}. The multivariate model is
specified as:
Yit,3 = f
⎛
⎝x ′i,t−1β3 +
J∑
j=1
δj3Dijt
+
3∑
k=2
αk3Mikt + γ Sit + uit,3
)
, t ∈ {2, 3}
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Drug A Drug A Drug A
Epoch 1A Epoch 2A Epoch 3A
t=1: enrollment t=2: 3 months t=3: 6 months t=4: 12 months
Epoch 1A: Epoch 1 for drug A
Epoch 2A: Epoch 2 for drug A
Epoch 3A: Epoch 3 for drug A
Drug A Drug B Drug B
Epoch 1A Epoch 1B
t=1: enrollment t=2: 3 months t=3: 6 months t=4: 12 months
Epoch 1A: Epoch 1 for drug A
Epoch 1B: Epoch 1 for drug B
Drug A Drug A Drug B
Epoch 1A Epoch 2A
t=1: enrollment t=2: 3 months t=3: 6 months t=4: 12 months
Epoch 1A: Epoch 1 for drug A
Epoch 2A: Epoch 2 for drug A
(a)
(b)
(c)
Figure 1. Epoch analysis. (a) Patient who stays on the same medication over 12 months. (b) Patient who switches medication
after the first 3 months. (c) Patient who switches medication after 6 months.
where Dijt is the treatment indicator, Dijt = 1 when a pa-
tient is prescribed drug j and 0 otherwise, β3 measures the
effects of the baseline covariates, and δj3 are the incremental
treatment effects on cost or change in EQ-5D tariff relative
to the excluded treatment, which we will refer to as drug B.
The variable Mikt is an indicator variable for multiple drug
use. Mikt = 1 when a patient takes k drugs simultaneously,
with k equal to 2 or 3. The indicator variable Sit = 1 when
a patient has switched medication after 3 months, and for
those patients we include two observations. The vector of
confounders x contains information on variables, including
age, gender, and country of residence of the patients, and
various comorbidity measures. It further includes a full set
of investigator indicators to allow for possible differential
investigator effects that may be correlated with prescription
choices. The full list of baseline covariates is given in Table 1.
For those patients that do not switch medication at t = 2 and,
therefore, have one observation in the first epoch, xi,t−1 are
the confounders measured at the first visit. For those who
switch medication at t = 2, xi,t−1 measures the confounders
at baseline for the first observation period, but for the sec-
ond observation, it measures the confounders observed at the
second visit t = 2.
Second Epoch. Denote Yi3,3|3 as the dependent variable
for the second 3-month epoch, given that the patient already
had 3 months of continuous treatment on the same medication
as that in the second epoch. The model is then specified as:
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Table 1. List of Baseline Covariates Used for Adjustment in
the Models
• Age upon presentation
• Age squared
• Age at first service contact for schizophrenia
• Suicide attempts 6 months before enrollment
• Body mass index at previous visit/baseline
• Weight in kilograms at baseline
• Variable indicating whether the patient is using antipsychotics
for the first time
• Treatment received 6 months before baseline
• Receiving an antipsychotic upon presentation to the baseline
visit
• Receiving mood stabilisers upon presentation
• Positive symptoms at baseline (CGI)
• Negative symptoms at baseline (CGI)
• Cognitive symptoms at baseline (CGI)
• Depressive symptoms at baseline (CGI)
• Overall symptom severity at baseline (CGI)
• Presence of extrapyramidal symptoms at baseline
• Tardive dyskinesia at baseline
• Loss of libido at baseline
• Presence of amenorrhea/other menstrual disturbance at baseline
• Presence of impotence/sexual dysfunction at baseline
• Patient’s compliance/adherence to prescribed antipsychotic
therapy during the past 4 weeks before baseline
• Substance dependency and/or abuse 4 weeks before baseline
• Alcohol abuse/dependency 4 weeks before baseline
• Receiving monotherapy or combination treatment at baseline
• Psychiatrist indicators
• Employment status in the 4 weeks before recruitment
• Gender
• Housing status in the 4 weeks before recruitment
• Resource use 6 months before enrollment (only for cost models)
• Score of dependent variable at baseline
CGI, Clinical Global Impression scale.
Yi3,3|3 = f
⎛
⎝x ′i1β3|3 +
J∑
j=1
δj3|3Dij3 +
3∑
k=2
αk3|3Mikt + ui3,3|3
⎞
⎠
where β3|3 measures the effects of the baseline covariates,
and δj3|3 are the incremental treatment effects on costs or
changes in EQ-5D tariff.
Third Epoch. Denote Yi4,6|6 as the dependent variable for
the third epoch, a 6-month period, given that the patient
already had 6 months of continuous treatment on the same
medication. The model is then specified as:
Yi4,6|6 = f
⎛
⎝x ′i1β6|6 +
J∑
j=1
δj6|6Dij4 +
3∑
k=2
αk6|6Mikt + ui4,6|6
⎞
⎠
where β6|6 measures the effects of the baseline covariates,
and δj6|6 are the incremental treatment effects.
When the dependent variable is the change in EQ-5D tar-
iff data, the models are estimated using ordinary least squares
(OLS), that is, a linear f for each of the three epochs. When
the dependent variable is cost, f is specified as an exponential
mean function to take account of the skewed distribution of
the cost data. Although the cost data are clearly nondiscrete,
the parameters can be consistently estimated using standard
Poisson regression models. A modified Park (15) test devel-
oped by Santos Silva and Tenreyro (18) indicated that this
specification is adequate for these data relative to other types
of distributions, such as the Gamma or inverse-Gaussian.
Also, unlike the latter, the Poisson specification gives equal
weight to extreme values (18), which is advantageous as data
from patients that are high resource users should be given
equal weight to those from low resource users.
Incremental Cost and QALYs Gained over
12 Months
When an exponential function is used, the estimated treat-
ment effects are multiplicative such that (exp(ˆδj ) − 1) gives
the estimated percentage change in treatment cost. To cal-
culate the incremental cost, we took as a reference cost the
average predicted cost for the sample as a whole, assuming
that all patients were drug B users. For example, for the first
epoch:
ˆCB3 =
1
N
N∑
i=1
exp(x ′i,t−1 ˆβ3 + γˆ Sit )
where ˆβ3 and γˆ are the estimated coefficients. The incremen-
tal costs for drug j are then calculated as (exp(ˆδj3) − 1) ˆCB3 .
The total cost differentials over the 12-month period can be
obtained by adding up the incremental costs figures over the
three epochs.
As discussed above, when the dependent variable is the
change in EQ-5D tariff data, the models are linear and es-
timated by OLS. To estimate the QALYs gained using the
coefficients from the models for change in EQ-5D, the ad-
ditional QALYs gained over the 12-month period for drug j
relative to drug B were approximated by:
QALYgained over 12 months
= ((3/12) × ˆδj3) × 0.5 for the first epoch
+ (3/12) × ˆδj3) + ((3/12) × ˆδj3|3)
× 0.5 for the second epoch
+ (6/12) × ( ˆδj3 + ˆδj3|3)+ ((6/12) × ˆδj6|6)
× 0.5 for the third epoch
The above numerical presentation is equivalent to measuring
the area under the curve of the difference in treatment effects
(see Figure 2).
For the cost and change in EQ-5D models, adding up the
effects was only possible as the models for the later periods
were conditional on the patient having continuous treatment
up to the point of analysis. The incremental cost-effectiveness
ratio (ICER) was finally estimated as the incremental costs,
as estimated above, divided by the QALYs gained over the
12-month period.
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Figure 2. Estimating quality-adjusted life-years (QALYs) gained from model coefficients.
Dealing with Uncertainty
Uncertainty in the analysis can be addressed using conven-
tional statistical techniques such that standard errors of the
ˆδ coefficients and the associated confidence intervals can be
estimated for each of the regression models to show param-
eter uncertainty within each epoch.
Uncertainty in the sampling was addressed by using non-
parametric bootstrapping to replicate the incremental treat-
ment effects. Two hundred samples were sampled randomly,
with replacement from the data of each patient, each sam-
ple providing data to estimate the corresponding incremental
cost and QALYs gained (1). Uncertainty in the ICER decision
rule was addressed using the bootstrap replications of incre-
mental costs and utilities to calculate the cost-effectiveness
acceptability curve of drug A compared with drug B. Each
replication of the incremental costs and utilities was used to
re-estimate the ICER. The probability that drug A is cost-
effective compared with drug B was estimated as the pro-
portion of replicated ICER falling below a specified value
assigned to the willingness to pay for a QALY gained. For
example, the National Institute of Clinical Excellence thresh-
old for the willingness to pay for QALY gained is around
£30,000 (5).
RESULTS
We present an example of the above methodological frame-
work, whereby the incremental cost and additional QALYs
gained are estimated for one antipsychotic, drug A, relative
to drug B, using the first 12 months of data on resource use
and EQ-5D tariffs collected within the SOHO study.
For purposes of this study, we have used UK unit costs
for medication use, hospital inpatient days, psychiatric ses-
sions and day care. These unit costs were taken from pub-
lished sources (11–14) and applied to volume of resource
use taken from the pan-European SOHO data. The treatment
assigned to the epoch was assumed to be the medication
received immediately before the assessment visit. Table 2
gives the incremental treatment effects on costs and changes
in EQ-5D tariff estimated for drug A compared with drug
B for each of the epochs. The results show that the total
treatment costs for patients using drug A are on average
£81 higher than those for patients treated with drug B in
the first epoch, although there is quite a large uncertainty
attached to this finding, as indicated by the large bootstrap
standard error of 58. In contrast, for the second and third
epochs, the total treatment costs for patients using drug A
are on average £114 and £157 lower, respectively, than for
patients using drug B. Over the 12-month period, the total
treatment costs are, therefore, on average £190 lower for
patients using drug A, with a bootstrap standard error of
130.
The estimation results of the model for changes in EQ-
5D show that drug A is less effective than drug B for the
first 3-month epoch. The estimated coefficient is −0.0443
with a very small bootstrap standard error of 0.0066, indi-
cating that this finding is a statistically significant incremen-
tal difference. For the second epoch, the estimated ˆδA3|3 is
very close to zero, −0.0034, and not significant. In the third
epoch, drug A is again marginally less effective, with an es-
timated incremental difference of ˆδA6|6 = −0.0117, with a
bootstrap standard error of 0.0077. The resulting incremen-
tal QALYs lost for drug A users over the 12-month period is
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Table 2. Estimation Results
Cost model (dependent variable: total treatment costs), drug A versus drug B
Poisson regression
First epoch (0–3 months)
exp(ˆδA3 − 1) ˆCB3
Second epoch (3–6
months) exp(ˆδA3|3 − 1) ˆCB3|3
Third epoch (6–12 months)
exp(ˆδA6|6 − 1) ˆCB6|6 Sum
No. of observationsa 6152 4356 3496
Coefficient 81.44 −114.13 −157.46 −190.15
Bootstrap standard error 57.61 47.54 81.71 130.04
95% CI −31.48, 194.36 −207.32, −20.95 −317.62, 2.71 −445.03, 64.73
Change in EQ-5D model (dependent variable: EQ-5D), drug A versus drug B
OLS
First epoch (0–3 months)
ˆδA3
Second epoch (3–6
months) ˆδA3|3
Third epoch (6–12 months)
ˆδA6|6 QALY
No. of observationsa 8303 5881 4730
Coefficient −0.0443 −0.0034 −0.0117 −0.0438
Bootstrap standard error 0.0066 0.0070 0.0077 0.0057
95% CI −0.0573, −0.0313 −0.0171, 0.0103 −0.0267, 0.0033 −0.0551, −0.0326
a For full sample, including patients using other drugs.
CI, confidence interval; OLS, ordinary least squares; QALY, quality-adjusted life-years.
estimated to be −0.0438, with a small bootstrap standard
error of 0.0057.
Combining the results of the cost and effectiveness mod-
els, we find that the incremental cost of drug B over the
12 months is £190 and the QALYs gained are 0.0438, giving
an incremental cost per QALY gained of £4,341. Figure 3
presents the incremental cost-effectiveness plane using the
incremental cost and effectiveness estimates from the 200
bootstrap samples. These give a good indication of the un-
certainty associated with the incremental cost per QALYs
gained. Also shown for the purpose of illustration is the
£30,000 per QALY gained threshold. If this threshold is
taken as society’s willingness to pay for a QALY gained,
then the probability that drug B is cost-effective relative to
drug A is 1, as all the bootstrap ICER estimates show the
incremental cost per QALY gained to be below the £30,000
threshold.
The cost-effectiveness acceptability curve depicted in
Figure 4 shows the probability of drug B being cost-effective
compared with drug A. The probability of being cost-
effective increases to 1 for values of around £16,000 per
QALY gained or more.
DISCUSSION
Observational studies offer the opportunity to study patients
in the everyday clinical setting. Unlike RCTs, where the treat-
ments are protocol driven and there are strict entry criteria,
observational studies can reflect the complexity of everyday
clinical practice. The course of treatments within the obser-
vation period, thus, can vary significantly between different
patients or practices. This finding is important in schizophre-
nia where it is well known that patients change medication
frequently (3).
In economic evaluation, the effects of each drug or treat-
ment on costs and effectiveness have to be estimated. This
study presents a methodological framework that allows the
treatment effects to be estimated in a longitudinal observa-
tional study where some patients have switched their medi-
cation or treatment.
The proposed epoch analysis is possible as the observa-
tional study is a “window” in the patients’ treatment pathway.
In the SOHO study, switching medication within the study
is equivalent to the entry criteria into the study. Switching
medication, thus, is essentially equivalent to a new baseline
measurement. However, it assumes that there is no carry over
of effects into the following epoch, which effectively means
that the effects of the medication wear off as soon as the
medication is discontinued.
One of the main advantages of the epoch analysis ap-
proach is that it is able to use data from all types of pa-
tients; from those who remain on the same therapy through-
out follow-up to those patients who took a combination of
medications and/or change medication.
Combination treatments are not modeled as separate
treatments. Instead, if a patient is taking more than one an-
tipsychotic treatment, then the effects are attributed to each of
the treatments received, and a “correction” combination coef-
ficient is fitted in the model by incorporating binary indicator
variables for combinations of two or three antipsychotics.
To control for the fact that the patients with repeated
observations for the first epoch may be inherently different
from those patients who do not switch treatment, a switch-
ing/repeated observation binary indicator is fitted in the mod-
els. The proposed approach allows for an accurate measure-
ment of the short-term effects of a medication and provides
the opportunity to use this information when estimating the
cumulative measure of effectiveness of treatment. This fea-
ture is important in schizophrenia as it is expected that most of
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Figure 3. Incremental cost effectiveness plane showing drug B versus drug A. QALYs, quality-adjusted life-years.
the improvements in clinical status will occur during the first
months after initiating or switching treatment. Thereafter,
the patients will most likely enter a maintenance treatment
phase (8).
The study also shows that the proposed framework al-
lows the application of accepted methods in the econometrics
literature to take into account the skewed nature of cost data
(10). The epoch analysis is also flexible enough to allow
for a reliable representation of uncertainty in sampling using
nonparametric bootstrap resampling and uncertainty in the
decision rule by means of the cost-effectiveness acceptabil-
ity curve (1).
In this study, we use UK unit costs and apply these
costs to the pan-European resource use data. It is recognized,
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Figure 4. Cost-effectiveness acceptability curve for drug B versus drug A. QALY, quality-adjusted life-year.
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however, that there is ongoing debate in the literature re-
garding the appropriate method of aggregating unit costs in
multinational studies (16;19).
Effectiveness and cost-effectiveness data from patients
in everyday clinical settings is becoming increasingly impor-
tant for reimbursement and access decisions. Longitudinal
observational studies provide a vehicle to address these data
needs. However, traditional methods of analysis are not ad-
equate when it comes to assigning treatment effects to the
drugs taken by patients when there is a tendency for them
to switch their medication frequently. We have proposed the
epoch analysis to address this issue. The approach is flexible
enough to incorporate current methods to address the mod-
eling of skewed cost data, sampling, and decision-making
uncertainty.
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